Comparative Pharmacology
Head-to-head clinical analysis: ANJESO versus NAPROSYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANJESO versus NAPROSYN.
ANJESO vs NAPROSYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby decreasing inflammation and pain.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This results in decreased inflammation, pain, and fever.
120 mg administered intravenously over 15 minutes, followed by 30 mg intravenously over 15 minutes, with the second dose given 12 to 24 hours after the first dose.
250-500 mg orally twice daily; maximum 1500 mg/day. For extended-release: 750-1000 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 1.5-2.5 hours in healthy adults. In elderly or renally impaired patients, half-life may extend to up to 6 hours.
Terminal elimination half-life is 12-17 hours. This long half-life allows twice-daily dosing, but may lead to drug accumulation in elderly or renally impaired patients.
Approximately 70% renal (30% unchanged, 40% as glucuronide conjugate), 30% fecal/biliary.
Renal excretion of conjugated metabolites accounts for approximately 95% of a dose, with 1-2% as unchanged naproxen. Fecal excretion is minimal (<5%).
Category C
Category C
NSAID
NSAID